# ScoreItem: VLDL Colesterol

**ID:** `019bf31d-2ef0-7842-a7b2-68b0e3ea9154`
**FullName:** VLDL Colesterol (Exames - Laboratoriais)
**Unit:** mg/dL

**Preparation Metadata:**
- Quality Grade: **EXCELLENT**
- Total Chunks: 30 de 11 artigos
- Avg Similarity: 0.674

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7842-a7b2-68b0e3ea9154`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7842-a7b2-68b0e3ea9154",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** VLDL Colesterol (Exames - Laboratoriais)
**Unidade:** mg/dL

**30 chunks de 11 artigos (avg similarity: 0.674)**

### Chunk 1/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.708

, apoiando a personaliza√ß√£o baseada em perfis de risco cumulativos, n√£o em um √∫nico marcador.
**Achados Adicionais**
- O cardi√¥metro de mortalidade cardiovascular iniciou monitoramento em 11/6/2024, contextualizando a urg√™ncia de interven√ß√µes cont√≠nuas.
- Diretrizes de tratamento costumam usar um limiar de 7,5% de risco para estatinas, mas exemplos pr√°ticos ilustram faixas de 2‚Äì4% em que a decis√£o deve considerar CAC e ApoB.
- Quase 40% dos indiv√≠duos com LDL muito elevado podem n√£o apresentar aterosclerose, refor√ßando heterogeneidade do risco.
- Colesterol total de 300 frequentemente acompanha LDL >190, mas a decis√£o terap√™utica deve ser guiada por risco global.
- Revis√µes de 2019 na Annals of Internal Medicine sobre carne vermelha/processada fornecem contexto adicional para dietas cardiometab√≥licas.
- Editorial de 2020 sobre hipercolesterolemia familiar difundiu o conceito ‚ÄúPower of Zero‚Äù, ampliando o uso do CAC na estratifica√ß√£o.

---

### Chunk 2/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.708

and their remnants and 
a¬†signiÔ¨Åcant risk of ASCVD dependent on them, 
were considered hypertriglyceridaemia (Table I) [26, 27]. Such a¬†division is also currently recom-mended by PSLD/PoLA experts (2024).

Arch Med Sci 2, March / 2024 363
RecommendationsIncreased plasma/serum TG levels are associated with signiÔ¨Åcant cardiovascular risk dependent, among oth-
ers, on the accumulation of TRL and their remnants. 
Moderately increased fasting TG levels > 150 mg/
dl (1.7 mmol/l) are an indication for treatment of hy-
pertriglyceridaemia, which should aim for TG levels  < 100 mg/dl (1.1 mmol/l).Total cholesterolCholesterol is one of the best-known lipids, which results, among others, from its direct con-nection with the development of atherosclerosis.

---

### Chunk 3/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIV (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.704

- [ ] 2. Para pacientes com s√≠ndrome metab√≥lica, considerar estrat√©gia Mediterr√¢nea organizada; preferir vers√£o com restri√ß√£o cal√≥rica combinada com atividade f√≠sica, monitorando resultados aos 6 e 12 meses.
- [ ] 3. Solicitar perfil lip√≠dico ampliado em casos selecionados: HDL, triglicer√≠deos, insulina, PCR, LDL oxidado e, quando indicado, subfracionamento de LDL; evitar decis√µes baseadas apenas em LDL total.
- [ ] 4. Planejar exames de risco cardiovascular conforme necessidade: score de c√°lcio coronariano e angiotomografia de coron√°rias (incluindo avalia√ß√£o de placas moles) quando o contexto cl√≠nico justificar.
- [ ] 5. Revisar e atualizar protocolos internos sobre √°lcool: remover recomenda√ß√µes de consumo ‚Äúcardioprotetor‚Äù; educar pacientes sobre riscos de c√¢ncer e piora do sono; avaliar predisposi√ß√£o/sensibilidade individual.
- [ ] 6.

---

### Chunk 4/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** discussion | **Similarity:** 0.697

. Curr Atheroscler Rep 2017; 19: 31.19. Boekholdt SM, Arsenault BJ, Mora S, et al. Association 
of LDL cholesterol, non-HDL cholesterol, and apolipopro-tein B levels with risk of cardiovascular events among 
patients treated with statins: a¬†meta-analysis. JAMA 
2012; 307: 1302-9. 20. Park JK, Bafna S, Forrest IS, et al. Phenome-wide Men-
delian randomization study of plasma triglyceride levels 
and 2600 disease traits. Elife 2023; 12: e80560.21. Trinder P. Determination of glucose in blood using glu-
cose oxidase with an alternative oxygen acceptor. Ann 
Clin Biochem 1969; 6: 24-7.22. Siedel J, Schmuck R, Staepels J, et al. Long term stable, liquid ready-to-use monoreagent for the enzymatic as-say of serum or plasma triglycerides (GPO-PAP-method). AACC Meeting Abstract 34. Clin Chem 1993; 39: 1127.23. Yang N, Wang M, Liu J, Liu J, Hao Y, Zhao D; Ccc-Acs In-
vestigators.

---

### Chunk 5/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.696

50%Moderate< 100< 2.6Low< 115< 3.0Alarming levels:Suspected homozygous familial hypercholesterolaemia:In untreated individuals> 500> 13.0In treated individuals> 300> 7.8Suspected heterozygous familial hypercholesterolaemia> 190> 4.9Unit conversion: [mg/dl] √ó 0.026 = [mmol/l].less, as with the use of other formulas, the accu-racy of non-HDL-C calculation depends on the bi-ological and analytical variability of TC and HDL-C concentrations. However, the biological variability 
of HDL-C levels is much lower than that of other lipid parameters, especially TG. In addition, HDL-C concentrations are much lower than the TC levels, which minimises their eÔ¨Äect on changes in calcu-lated non-HDL-C concentrations.Reporting of resultsAlongside the calculated non-HDL-C level, a¬†laboratory report should include information on 

Arch Med Sci 2, March / 2024 369the desirable (target) values with regard to cardio-vascular risk (Table VI).

---

### Chunk 6/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.695

co da dislipidemia.
- [ ] 2. Analisar criticamente os estudos sobre o Inclisiran (Cibrava), focando na diferen√ßa entre desfechos substitutos (redu√ß√£o de LDL) e desfechos cl√≠nicos duros (mortalidade, infarto, AVC).
- [ ] 3. Utilizar o site `the-nnt.com` para pesquisar o NNT e NNH de outros medicamentos prescritos na pr√°tica cl√≠nica.
- [ ] 4. Refletir sobre a influ√™ncia da ind√∫stria farmac√™utica e dos interesses financeiros na prescri√ß√£o de novos medicamentos.
- [ ] 5. Estudar a diferen√ßa entre risco relativo e risco absoluto para interpretar criticamente os achados de estudos cient√≠ficos.
- [ ] 6. Pesquisar sobre os diferentes tipos de √¥mega-3 (EPA, DHA, ALA) e suas formula√ß√µes para entender como a qualidade do suplemento afeta os resultados.
- [ ] 7. Investigar os exames de subfracionamento de LDL e a rela√ß√£o ApoA/ApoB como ferramentas de avalia√ß√£o de risco cardiovascular mais precisas que o LDL total.
- [ ] 8.

---

### Chunk 7/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** introduction | **Similarity:** 0.693

ffective monitoring (after therapy 
initiation), and in the consequence to avoid the first and recurrent cardio-
vascular events.Key words: lipid disorders, low-density lipoprotein cholesterol,  high-density lipoprotein cholesterol (HDL-C), triglicerides, non-HDL-C, guidelines, laboratory diagnostics.
Editor¬ís choice 

358 Arch Med Sci 2, March / 2024IntroductionThe lipid proÔ¨Åle routinely performed to assess cardiovascular risk involves the measurement/calculation of serum/plasma levels of total cho-
lesterol (TC), high-density lipoprotein cholester-ol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and non-HDL choles-terol (non-HDL-C), although LDL-C level is still the most important factor in both the diagnosis and 
monitoring of the course and treatment of lipid 
disorders and the prediction of cardiovascular in-
cidents [1¬ñ4].

---

### Chunk 8/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** methods | **Similarity:** 0.689

d include information on 

Arch Med Sci 2, March / 2024 369the desirable (target) values with regard to cardio-vascular risk (Table VI).
RecommendationsNon-HDL-C is an indicator of cardiovascular risk, partic-ularly recommended in individuals with TG levels > 200 
mg/dl (2.3 mmol/l), obesity, type 2 diabetes, metabolic 
syndrome and low TC and LDL-C levels. 
Based on the PoLA Guidelines (2021) it is equivalent to 
LDL-C cholesterol as a¬†predictor and should be assessed in 
every patient as a¬†permanent element of the lipid proÔ¨Åle. Apolipoprotein B Apolipoprotein B (apoB), which is a¬†structural component of all lipoproteins except for HDL, ex-ists in two isoforms: apoB100 (MM 550 kD), syn-
thesised in hepatocytes and present in VLDL, IDL and LDL, and its fragment, apoB48 (MM 265 kD), synthesised in enterocytes and present in CM and their remnants [10, 69].Methods of determinationSerum/plasma apoB is determined by immuno- turbidimetry and immunonephelometry.

---

### Chunk 9/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.686

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 10/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.682

maior que TG, mas ainda pode haver LDL de baixa qualidade, refor√ßando limita√ß√µes do uso isolado da raz√£o.
- Colesterol remanescente (IDL, VLDL, quilom√≠crons) estimado por total ‚Äì (HDL+LDL): exemplo 220 ‚Äì (40+150) = 30, destacando fra√ß√£o mais aterog√™nica.
- Oxida√ß√£o de LDL: anti-LDL oxidado ideal at√© 25; valor de 27,5 indica maior estresse oxidativo e motiva estrat√©gias para aumentar tamanho pico e reduzir oxida√ß√£o.
**Benef√≠cio absoluto de f√°rmacos/alternativas em preven√ß√£o prim√°ria √© modesto; interven√ß√µes podem ser valiosas em preven√ß√£o secund√°ria com metas moderadas e combina√ß√µes.**
- Redu√ß√£o relativa m√©dia de risco com estatina ~20%; em baixo risco (2% em 10 anos), redu√ß√£o absoluta ~0,4% e NNT ~250 (4 por 1.000), benef√≠cio muito pequeno; em risco extremo (40%), redu√ß√£o absoluta 8% (40%‚Üí32%).

---

### Chunk 11/30
**Article:** Cardiologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.682

√ß√£o triglicer√≠deos/HDL como infer√™ncia pr√°tica de risco: TG aproximadamente 2,5 vezes o HDL sugere maior presen√ßa de part√≠culas aterog√™nicas de LDL.
- √änfase de que n√∫meros isolados (LDL total, LDL oxidada, subfracionamento) n√£o s√£o ‚Äúbala de prata‚Äù; √© preciso avaliar o conjunto (inflama√ß√£o, oxida√ß√£o, glica√ß√£o, metila√ß√£o).
- Sugere que mesmo com LDL oxidada baixa, podem existir outras modifica√ß√µes (LDL glicada, inflamada) com risco ateroscler√≥tico.
- Destaca que reduzir apenas o n√∫mero de colesterol sem abordar a cadeia causal (excesso de carboidratos, resist√™ncia insul√≠nica) √© insuficiente.
- N√£o h√° queixa espec√≠fica do paciente registrada; o conte√∫do √© educacional, incluindo interpreta√ß√£o de exames e impacto de polimorfismos gen√©ticos no metabolismo lip√≠dico e risco cardiovascular.
## Objetivo:
- Refer√™ncia a estudos indicando que cerca de 50% dos indiv√≠duos com LDL ‚Äúnormal‚Äù (‚â§100 mg/dL) apresentam aterosclerose aos 50 anos.

---

### Chunk 12/30
**Article:** Cardiologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** introduction | **Similarity:** 0.679

ropor√ß√£o de LDL aterog√™nico.
- Classifica√ß√£o pr√°tica: 
  - Risco baixo em faixas como TG ~100‚Äì125 e HDL ~50.
  - Acima disso: risco m√©dio a alto, conforme contexto.
- TG elevado (exclu√≠das condi√ß√µes gen√©ticas raras) indica consumo exagerado de carboidratos e desbalan√ßo com individualidade (idade, metabolismo, exerc√≠cio, polimorfismos).
### 4. Cadeia causal metab√≥lica e estrat√©gia de interven√ß√£o
- Fluxo t√≠pico: excesso de carboidratos ‚Üí ‚Üë TG, CT, LDL, insulina de jejum, HbA1c.
- Maior impacto do colesterol end√≥geno derivado da dieta sobre produ√ß√£o hep√°tica, n√£o do colesterol alimentar direto.
- Foco terap√™utico: reduzir a causa inicial (excesso de carboidratos), n√£o apenas baixar n√∫meros.
### 5. Exames de LDL oxidada e anti-LDL oxidada: interpreta√ß√£o e limita√ß√µes
- LDL oxidada: medida direta do ant√≠geno; mais fidedigna.
- Anti-LDL oxidada: anticorpos que podem n√£o acompanhar a LDL ox por depura√ß√£o/metaboliza√ß√£o.

---

### Chunk 13/30
**Article:** Cardiologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.678

jum, insulina de jejum, hemoglobina glicada.
  - Considerar ApoA1 e ApoB; calcular raz√£o ApoA/ApoB.
  - Em casos de alto risco ou discord√¢ncia entre exames, considerar angiotomografia de coron√°rias com escore de c√°lcio.
  - Quando pertinente, considerar avalia√ß√£o gen√©tica para polimorfismos (LDLR, APOE, ABCG5/8, FADS1/2, TCF7L2, HMGCR, LIPC, APOC3), sempre interpretando em conjunto com cl√≠nica e h√°bitos.
- Plano de Tratamento de Seguimento:
  - Interven√ß√µes de estilo de vida visando reduzir consumo excessivo de carboidratos e ajustar dieta √† individualidade metab√≥lica.
  - Incentivar atividade f√≠sica regular para melhorar perfil lip√≠dico e sensibilidade √† insulina.
  - Monitorar periodicamente rela√ß√£o triglicer√≠deos/HDL e marcadores de oxida√ß√£o/glica√ß√£o da LDL.
  - Ajustar plano alimentar conforme resposta individual; evitar dietas cetog√™nicas/low carb a longo prazo em indiv√≠duos com eleva√ß√£o excessiva de colesterol/LDL possivelmente por polimorfismos (p.

---

### Chunk 14/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.677

il√¢ncia aumentada nas mulheres.**
- Pr√©-menopausa: incid√™ncia de eventos cardiovasculares em mulheres √© muito menor (raz√µes 1:20 a 1:30 versus homens).
- P√≥s-menopausa: aproxima√ß√£o para quase 1:1, refletindo a perda do efeito protetor do estrog√™nio e a mudan√ßa no perfil de risco.
**Additional Key Findings**
- Limiares de exposi√ß√£o/oxida√ß√£o do LDL: acima de 0,8 h√° maior exposi√ß√£o do LDL √† oxida√ß√£o; alvo desej√°vel ‚â§0,7‚Äì0,8.
- Evid√™ncia hist√≥rica (Interarte, 2004) e revis√µes recentes (2023) sustentam a evolu√ß√£o do conhecimento sobre D, resist√™ncia √† insulina e risco cardiovascular.
- Lp(a) tem ~90% de variabilidade gen√©tica, indicando forte determina√ß√£o heredit√°ria e necessidade de estrat√©gias espec√≠ficas.
- Semaglutida em IC diast√≥lica e obesidade: estudo com n=529 mostrou redu√ß√£o de peso de 10% e apenas 1 evento de morte por IC no grupo tratado, sugerindo benef√≠cio cl√≠nico.

---

### Chunk 15/30
**Article:** Cardiologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.676

# Perguntas dos Alunos
Nenhuma pergunta foi registrada.

---

## SOAP

> Data e Hora: 2025-11-20 20:40:15
> Paciente:
> Diagn√≥stico:
## Hist√≥rico do Diagn√≥stico:
1. Hist√≥rico M√©dico:
2. Hist√≥rico de Medica√ß√µes: Insira mais aqui
## Subjetivo:
- Conversa educativa sobre cardiologia metab√≥lica funcional e integrativa, com foco em perfil lip√≠dico, risco ateroscler√≥tico e individualiza√ß√£o conforme gen√©tica e resposta cl√≠nica.
- Discuss√£o sobre qualidade do LDL (subtipos, oxida√ß√£o, glica√ß√£o, inflama√ß√£o) e rela√ß√£o com triglicer√≠deos e HDL.
- Observa√ß√£o de que triglicer√≠deos elevados, fora raras condi√ß√µes gen√©ticas, costumam refletir consumo excessivo de carboidratos, sedentarismo, idade avan√ßada, menor metabolismo basal e predisposi√ß√£o gen√©tica.
- Recomenda rela√ß√£o triglicer√≠deos/HDL como infer√™ncia pr√°tica de risco: TG aproximadamente 2,5 vezes o HDL sugere maior presen√ßa de part√≠culas aterog√™nicas de LDL.

---

### Chunk 16/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** abstract | **Similarity:** 0.673

34. Clin Chem 1993; 39: 1127.23. Yang N, Wang M, Liu J, Liu J, Hao Y, Zhao D; Ccc-Acs In-
vestigators. The level of remnant cholesterol and impli-
cations for lipid-lowering strategy in hospitalized pa-
tients with acute coronary syndrome in China: Ô¨Åndings 
from the improving care for cardiovascular disease in 
China-Acute Coronary Syndrome Project. Metabolites 
2022; 12: 898. 24. Doi T, Langsted A, Nordestgaard BG. Elevated remnant 
cholesterol reclassiÔ¨Åes risk of ischemic heart disease 
and myocardial infarction. J Am Coll Cardiol 2022; 79: 
2383-97. 25. Quispe R, Martin SS, Michos ED, et al. Remnant choles-
terol predicts cardiovascular disease beyond LDL and 
ApoB: a¬†primary prevention study. Eur Heart J 2021; 42: 
4324-32. 26. Moulin P, Dufour R, Averna M, et al. IdentiÔ¨Åcation and di-
agnosis of patients with familial chylomicronaemia syn-
drome (FCS): Expert panel recommendations and propos-al of an ¬ìFCS score¬î. Atherosclerosis 2018; 275: 265-72.27. Ginsberg HN, Packard CJ, Chapman MJ, et al. Triglycer-ide-rich lipoproteins and their remnants: metabolic 
insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies ¬ñ a¬†consensus 
statement from the European Atherosclerosis Society. 
Eur Heart J 2021; 42: 4791-806.28. Rynkiewicz A, Cybulska B, Banach M, et al. Management of familial heterozygous hypercholesterolemia: position paper of the Polish Lipid Expert Forum. J Clin Lipidol 2013; 7: 217-21.29. Marx N, Federici M, Sch√ºtt K, et al.; ESC ScientiÔ¨Åc Docu-ment Group. 2023 ESC Guidelines for the management 
of cardiovascular disease in patients with diabetes. Eur 
Heart J 2023; 44: 4043-140. 30. Visseren FLJ, Mach F, Smulders YM, et al.; ESC National 
Cardiac Societies; ESC ScientiÔ¨Åc Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-337. 31. Li LH, Dutkiewicz EP, Huang YC, et al. Analitycal methods for cholesterol quantiÔ¨Åcation. J Food Drug Ann 2019; 27: 375-86.32. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol 
determination in high-density lipoproteins separated by three diÔ¨Äerent methods. Clin Chem 1977; 23: 882-4.33. Allain CC, Poon LS, Chan CS, et al. Enzymatic determi-nation of total serum cholesterol. Clin Chem 1974; 20: 
470-5.34. Ganjali S, Mahdipour E, Aghaee-Bakhtiari SH, et al. Com-
positional and functional properties of high-density li-
poproteins in relation to coronary in-stent restenosis. 
Arch Med Sci 2021; 19: 57-72. 35. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a¬†novel import-ant diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.36. Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrif-
ugation to homogeneous assays. Clin Chem 2001; 47: 
1579-96.37. Camont L, Chapman MJ, Kontush A. Pendal activities of 
HDL subpopulations and their relevance to cardiovascu-
lar disease. Trends Mol Med 2011; 17: 596-605.38. Martin SS, Jones SR, Toth PP. High-density lipoprotein 
subfractions: current views and clinical practice applica-tions. Trends Mol Med 2014; 26: 328-36.39. Kosmas CE, Martinez I, Sourlas A, et al. High-densi-
ty lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context 
2018; 7: 212-25.40. Movvo R, Rader DJ. Laboratory assessment of HDL het-
erogeneity and function. Clin Chem 2008; 54: 788-801.41. Rosenson RS, Brewer HB, Chapman MJ, et al. HDL mea-
sures, particle heterogeneity, proposed nomenclature, 
and relation to atherosclerotic cardiovascular events. 
Clin Chem 2011; 57: 392-410.42. Sean Davidson W. HDL-C vs HDL-P: how changing one 
letter could make a¬†diÔ¨Äerence in understanding the role 
of high-density lipoprotein in disease. Clin Chem 2014; 
60: e1-3.43. Kidawa M, Gluba-Brz√≥zka A, Zielinska M, et al. Choles-
terol subfraction analysis in patients with acute coro-
nary syndrome. Curr Vasc Pharmacol 2019; 17: 365-75.44. Rizzo M, Otvos J, Nikolic D, et al. Subfractions and sub-
populations of HDL: an update. Curr Med Chem 2014; 
21: 2881-91.45. Sonmez A, Nikolic D, Dogru T, et al. Low- and high-den-sity lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J Clin Lipidol 2015; 9: 576-82.46. Annema W, von Eckardstein A. Dysfunctional high-densi-ty lipoproteins in coronary heart disease: implication for diagnostics and therapy. Translat Res 2016; 173: 30-57.47. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dys-
functional HDL: a¬†novel important diagnostic and ther-

---

### Chunk 17/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.671

 s modiÔ¨Åcation. 1Based on the PSC/PoLA 2024 Guidelines [81].Lipid proÔ¨Åle ¬ñ laboratory reportLipid proÔ¨Åle includes a¬†battery of blood serum or plasma tests and calculations aimed at identiÔ¨Å-cation of dyslipidemia as a¬†cardiovascular risk fac-tor, deÔ¨Åning the recommendations and  treatment  
monitoring, including:¬ñ total cholesterol (TC) level,¬ñ HDL cholesterol level (HDL-C),¬ñ LDL cholesterol level (LDL-C),¬ñ non-HDL cholesterol level (non-HDL-C),
¬ñ triglyceride (TG) level,¬ñ  lipoprotein (a) level [Lp(a)] (determined at least once in life ¬ñ see PCS/PoLA 2024 recommenda-
tions [81]),¬ñ apolipoprotein B (apoB) level ¬ñ as indicated.In addition  to the results of measurements and calculations, a¬†lipid proÔ¨Åle laboratory report  (Table IX), should include information on how the LDL-C level was determined (calculated/deter-mined), as well as the target (desirable) and alarm-Table IX.

---

### Chunk 18/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.670

) s√£o mais aterog√™nicas.
    - **Efeito de Dietas e Medicamentos:** Dietas low-carb e medicamentos como inibidores de SGLT2 podem aumentar o LDL total, mas melhoram o perfil lip√≠dico ao reduzir as part√≠culas pequenas e densas.
    - **√îmega-3 e a Qualidade do LDL:** A suplementa√ß√£o com √¥mega-3 demonstrou aumentar o tamanho das part√≠culas de LDL, tornando-as menos aterog√™nicas, al√©m de reduzir triglicer√≠deos e ApoB.
    - **Apolipoprote√≠nas (ApoA/ApoB):** A rela√ß√£o entre ApoA (presente no HDL) e ApoB (presente no LDL) √© um marcador de risco cardiovascular mais relevante que o LDL isolado.
## ‚ùì Perguntas
- [Inserir Pergunta/Confus√£o]
## üìö Tarefas
- [ ] 1. Pesquisar e ler a diretriz de 2025 da American Association of Clinical Endocrinology sobre o tratamento farmacol√≥gico da dislipidemia.
- [ ] 2.

---

### Chunk 19/30
**Article:** Extremely high HDL cholesterol paradoxically increases the risk of all-cause mortality in non-diabetic males from the Korean population: Korean genome and epidemiology study-health examinees (KoGES-HEXA) cohorts (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.663

AC, Wong Y, Shiu SW, Tan KC. Carbamylated HDL and 
mortality outcomes in type 2 diabetes. 
Diabetes Care
. (2021) 44:804¬ñ9. doi: 
10.2337/dc20-2186
 42. Yang HS, Hur M, Kim H, Kim SJ, Shin S, Di Somma S. HDL subclass analysis in 
predicting metabolic syndrome in Koreans with high HDL cholesterol levels. 
Ann Lab 
Med
. (2020) 40:297¬ñ305. doi: 
10.3343/alm.2020.40.4.297
 43. Agarwala AP, Rodrigues A, Risman M, McCoy M, Trindade K, Qu L, et al. High-
density lipoprotein (HDL) phospholipid content and cholesterol eux capacity are 
reduced in patients with very high HDL cholesterol and coronary disease. 
Arterioscler 
romb Vasc Biol
. (2015) 35:1515¬ñ9. doi: 
10.1161/ATVBAHA.115.305504

---

### Chunk 20/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.660

if the pre-analytical 
requirements are met, tends to underestimate LDL-C levels at low values < 70 mg/dl (1.8 mmol/l). 
GPxFigure 6. Dysfunctional HDL particles: A¬†¬ñ HDL modiÔ¨Åed by myeloperoxidase, B ¬ñ inÔ¨Çammatory HDL SAA ¬ñ serum amyloid A, PON-1 ¬ñ paraoxonase-1, GPx ¬ñ glutathione peroxidase, RCT ¬ñ reverse cholesterol transport,  ABCA1 ¬ñ ATP-binding membrane cassette transporter A1.ABMPOApo A-IPON-1GPxApo A-IApo A-II‚Üì Macrophage RCT‚Üì ABCA1Apo A-IISAACeruloplasminApo A-IApo A-IIApo JSAACeruloplasminApo A-IPON-1

Arch Med Sci 2, March / 2024 367One of the recent modiÔ¨Åcations proposed to Friedewald formula is he Martin-Hopkins equation (2013) [59]: LDL-C = TC ¬ñ HDL-C ¬ñ TG/x (in mg/dl), where: x ¬ñ is the TG-VLDL-C ratio based on TG and non-HDL-C levels; values are available in spe-
cial tables or online calculators (https://ldlcalcula-tor.com).

---

### Chunk 21/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** results | **Similarity:** 0.660

by NCEP, is ¬±9% while the one used by COBJwDL is ¬±8% and this value is also recommended by PSLD/PoLA (2024).Reporting of resultsAlongside the TC level, a¬†laboratory report should include information on the desirable (tar-get) values with regard to cardiovascular risk (Ta-
ble II).HDL cholesterolHigh density lipoproteins (HDL), unlike other lipoproteins, are characterised by a¬†low lipid and high protein content. HDL transport about 25% of the cholesterol present in the blood, and its content 
in the particles of these lipoproteins varies consid-erably. Therefore, plasma HDL-C level provides in-direct and inaccurate information on HDL content in the blood. Nevertheless, HDL-C measurement re-mains a¬†basic test for the assessment of HDL con-
tent in the blood, as methods of direct measure-ment of the number of HDL particles (HDL-P), and their individual subfraction (measured with e.g.

---

### Chunk 22/30
**Article:** PEER simplified lipid guideline 2023 update: Prevention and management of cardiovascular disease in primary care (2023)
**Journal:** Canadian Family Physician
**Section:** abstract | **Similarity:** 0.659

Diretriz canadense PEER 2023 fornecendo algoritmo simplificado para manejo de dislipidemia em cuidados prim√°rios. Recomenda rastreamento lip√≠dico universal em adultos ‚â•40 anos e em adultos mais jovens com fatores de risco. Perfil lip√≠dico pode ser n√£o-jejum exceto se triglicer√≠deos pr√©vios >4,5 mmol/L (400 mg/dL). Estratifica risco usando calculadora Framingham ou ASCVD e identifica condi√ß√µes de muito alto risco (DCV estabelecida, diabetes ‚â•15 anos, DRC est√°gio 3+). Metas: LDL <2,0 mmol/L (77 mg/dL) ou redu√ß√£o ‚â•50% para alto risco; <1,8 mmol/L (70 mg/dL) para muito alto risco. Enfatiza abordagem n√£o-HDL como alvo secund√°rio (meta 30 mg/dL acima de LDL). Estatina de intensidade moderada a alta como terapia inicial; adicionar ezetimiba se meta n√£o atingida. Refor√ßa import√¢ncia de modifica√ß√µes estilo de vida (dieta mediterr√¢nea, exerc√≠cio 150 min/semana, cessa√ß√£o tabagismo) como base do tratamento. Intervalo de seguimento: 3 meses ap√≥s in√≠cio terapia, depois anualmente.

---

### Chunk 23/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.655

tion of Cardiovascular Disease, Division  
of Cardiology, Department of Medicine, Johns Hopkins University School  
of Medicine, Baltimore, MD, United StatesSubmitted: 15 December 2023; Accepted: 18 March 2024
Online publication: 18 March 2024Arch Med Sci 2024; 20 (2): 357¬ñ374DOI: https://doi.org/10.5114/aoms/186191
Copyright ¬© 2024 Termedia & Banach
2024 Guidelines of the Polish Society of Laboratory 
Diagnostics and the Polish Lipid Association on 
laboratory diagnostics of lipid metabolism disorders Bogdan Solnica1,2, Gra≈ºyna Sygitowicz1,3, Dariusz Sitkiewicz1,3, Jacek J√≥≈∫wiak4,5,  S≈Çawomir Kasperczyk4,6, Marlena Broncel4,7, Anna Wolska4,8, Gra≈ºyna OdrowƒÖ≈º-Sypniewska1,9, Maciej Banach4,10,11
AbstractLipid disorders are the most common (even 70%) and worst monitored car-diovascular risk factor (only 1/4 of patients in Poland and in CEE countries 
are on the low-density lipoprotein cholesterol (LDL-C) goal).

---

### Chunk 24/30
**Article:** Abordagem Funcional Integrativa Aplicada a Cada √Årea - Parte XIII (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.655

a AVC em 10 anos. Em contraste, para pacientes de alto risco, a redu√ß√£o de risco de infarto foi de 3%.
### 5. Complexidade do HDL e LDL na Sa√∫de Cardiovascular
- **HDL Alto:** Um estudo de coorte mostrou que participantes com HDL j√° alto (‚â•60 mg/dL) que o aumentaram ainda mais tiveram um risco maior de doen√ßa cardiovascular (Hazard Ratio de 1.15), desmistificando a ideia de que "quanto mais HDL, melhor".
- **Inibidores de SGLT2:** Uma meta-an√°lise mostrou que esses medicamentos, apesar de reduzirem o risco cardiovascular, aumentam o colesterol total, LDL e HDL. Isso levanta um paradoxo em rela√ß√£o √†s dietas low-carb, que t√™m efeito similar no perfil lip√≠dico e s√£o frequentemente criticadas.
### 6. Subpart√≠culas de LDL e sua Relev√¢ncia Cl√≠nica
- O LDL n√£o √© uma mol√©cula √∫nica, mas um conjunto de subtipos. As part√≠culas de LDL pequenas e densas (small dense LDL) s√£o mais aterog√™nicas.

---

### Chunk 25/30
**Article:** Cardiologia I (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.653

tab√≥licos: √°cidos graxos de cadeia longa produzidos em maior quantidade em sobrepeso; dieta focada exclusivamente neles pode aumentar inflama√ß√£o.
- Integra√ß√£o cl√≠nica: papel de VLDL/TG ap√≥s refei√ß√µes ricas em carboidratos; import√¢ncia de ApoB, TG e subfra√ß√µes de LDL na avalia√ß√£o de risco.
### 8. Interpreta√ß√£o cl√≠nica de HDL e ajustes de estilo de vida
- HDL geralmente positivo; aumento costuma refletir exerc√≠cio, √¥mega-3, monoinsaturados.
- HDL pode ser disfuncional quando muito alto (>90 mg/dL), especialmente se LDL tamb√©m alto; poss√≠vel redu√ß√£o do fluxo reverso de colesterol.
- Conduta: se HDL excessivo ap√≥s interven√ß√£o diet√©tica, reavaliar √°lcool, inflama√ß√£o, gen√©tica, consumo de gorduras; considerar reduzir excesso de lip√≠dios espec√≠ficos e suplementa√ß√£o; monitorar em 8‚Äì12 semanas.
- Marcadores auxiliares: ApoA-I, CETP, HDL-P por NMR quando dispon√≠vel.
### 9.

---

### Chunk 26/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.652

to de colesterol nos tecidos. Muita ApoB est√° associada a maior risco.
    - **Rela√ß√£o ApoB/ApoA:** √â um forte preditor de risco cardiovascular, superior aos n√≠veis isolados de colesterol.
*   **Subtipos de LDL (Padr√£o A vs. Padr√£o B):**
    - **Padr√£o A:** Part√≠culas grandes e flutuantes, ben√©ficas, que transportam colesterol para suas fun√ß√µes vitais.
    - **Padr√£o B:** Part√≠culas pequenas e densas, aterog√™nicas, que penetram e oxidam facilmente no endot√©lio. S√£o mais comuns em pessoas com resist√™ncia insul√≠nica e dieta rica em carboidratos.
*   **Conceito de "LDL Estragado":**
    - **LDL Oxidado, Glicado, Eletronegativo:** S√£o formas de LDL danificadas por estresse oxidativo e excesso de a√ß√∫car, tornando-se prejudiciais e impulsionando a aterosclerose.
*   **Colesterol Remanescente:** Calculado como (Colesterol Total - (HDL + LDL)), corresponde a part√≠culas (IDL, VLDL) consideradas altamente aterog√™nicas.
### 3.

---

### Chunk 27/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** methods | **Similarity:** 0.651

s with diabetes. Eur 
Heart J 2023; 44: 4043-140. 30. Visseren FLJ, Mach F, Smulders YM, et al.; ESC National 
Cardiac Societies; ESC ScientiÔ¨Åc Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42: 3227-337. 31. Li LH, Dutkiewicz EP, Huang YC, et al. Analitycal methods for cholesterol quantiÔ¨Åcation. J Food Drug Ann 2019; 27: 375-86.32. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol 
determination in high-density lipoproteins separated by three diÔ¨Äerent methods. Clin Chem 1977; 23: 882-4.33. Allain CC, Poon LS, Chan CS, et al. Enzymatic determi-nation of total serum cholesterol. Clin Chem 1974; 20: 
470-5.34. Ganjali S, Mahdipour E, Aghaee-Bakhtiari SH, et al. Com-
positional and functional properties of high-density li-
poproteins in relation to coronary in-stent restenosis. 
Arch Med Sci 2021; 19: 57-72. 35. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M.

---

### Chunk 28/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.651

11; 70: 
482-7.14. Colantonio LD, Bittner V, Reynolds K, et al. Association of serum lipids and coronary heart disease in contem-porary observational studies. Circulation 2016; 133: 256-64.15. Drexel H, Tamargo J, Kaski JC, et al. Triglycerides revis-ited: is hypertriglyceridaemia a¬†necessary therapeutic 
target in cardiovascular disease? Eur Heart J Cardiovasc Pharmacother 2023; 9: 570-82. 16. Banach M, Surma S, Reiner Z, et al. Personalized man-agement of dyslipidemias in patients with diabetes-it 
is time for a¬†new approach (2022). Cardiovasc Diabetol 
2022; 21: 263.17. Makover ME, Surma S, Banach M, Toth PP. Eliminating 
atherosclerotic cardiovascular disease residual risk. Eur 
Heart J 2023; 44: 4731-3.18. Dron JS, Hegele RA. Genetics of triglycerides and the risk of atherosclerosis. Curr Atheroscler Rep 2017; 19: 31.19. Boekholdt SM, Arsenault BJ, Mora S, et al.

---

### Chunk 29/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.651

vida e identificar fatores de risco para inflama√ß√£o e disfun√ß√£o endotelial (dieta, estresse, sedentarismo).
- [ ] 2. Utilizar a calculadora MESA Risk para determinar o risco cardiovascular dos pacientes e considerar a solicita√ß√£o do Escore de C√°lcio Coronariano antes de prescrever estatinas em preven√ß√£o prim√°ria.
- [ ] 3. Ao avaliar o risco cardiovascular, solicitar exames avan√ßados como a rela√ß√£o ApoB/ApoA, subpart√≠culas de lipoprote√≠nas e anti-LDL oxidado para uma an√°lise mais aprofundada.
- [ ] 4. Em pacientes de preven√ß√£o prim√°ria, mesmo com colesterol alto, priorizar mudan√ßas no estilo de vida antes de considerar o uso de estatinas.
- [ ] 5. Reservar o uso de estatinas principalmente para pacientes em preven√ß√£o secund√°ria ou de alt√≠ssimo risco, focando nos seus efeitos pleotr√≥picos.
- [ ] 6.

---

### Chunk 30/30
**Article:** 2024 Guidelines of the Polish Society of Laboratory Diagnostics and the Polish Lipid Association on laboratory diagnostics of lipid metabolism disorders (2024)
**Journal:** Archives of Medical Science
**Section:** other | **Similarity:** 0.650

-C by allowing the assessment of residual risk and, based on available studies, is 
more predictive of cardiovascular risk than LDL-C levels and most often equally predictive as apoB 
measurement reÔ¨Çecting the number of athero-genic lipoprotein particles [65, 66]. Non-HDL-cho-lesterol is now also a¬†recommended parameter in the assessment of cardiovascular risk in SCORE2 
and SCORE2-OP and, according to recent Polish recommendations, is the basis for the diagnosis of metabolic syndrome [67]. The non-HDL-C level is calculated according to the following formula: Non-HDL-C = TC ¬ñ HDL-C.The calculation of non-HDL-C is more reliable than the calculation of LDL-C [66, 68]. Neverthe-

368 Arch Med Sci 2, March / 2024Table IV. Updated (2024) cardiovascular risk categories according to the PoLA/CFPiP/PCS/PSLD/PDS/PSH 2021 guidelines.

---

